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Discussion and Conclusions 
SMase induces enhanced biphasic changes in the 
tone of db/db mice derived vessels and these 
effects are related to thromboxane A2 and 
endothelial nitric oxide. The increased relaxations 
require the activation of PLC and involve 
cystathionine-γ-liase (CSE). The altered dose-
response curves for NaHS, SNP and PE suggest 
that phosphodiesterase (PDE) activity might be 
enhanced in the aortas of db/db mice. Taken 
together our results indicate that an altered 
balance of gasotransmitters might contribute to 
the SMase induced and surprisingly enhanced 
vasorelaxations in db/db animal derived aortas. 
According to literature there is a 10-fold increase 
in the SMase-sensitive lipid raft area in db/db 
mice that inhibits eNOS activation by CAV-1 (10). 
Parallelly, H2S levels in cardiovascular tissues from 
db/db mice are reported to be lower (11).  These 
suggest decreased availability of the endogenous 
inhibitor of PDE and indicate that 
sphingomyelinase might lead to enhanced 
vasorelaxations by massively increased NO 
production. An interesting aspect of our results is 
that type 2 diabetic vascular tissues have bigger 
sensitivity to either endogenously or exogenously 
altered H2S levels. Taken together our 
observations strengthen the importance to 
achieve proper H2S levels in type 2 diabetic 
vascular tissues. 
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The use of W146, D-erythro-MAPP, Wortmannin 
and MK2206 did not alter the vasoactive effects 
of SMase in the wild type or db/db mice (Fig. 5). 
However, the PLC inhibitor U73122 and 
propargylglycin decreased (-2.21±1.06% and -
22.02±4.95% respectively, p<0.05) the SMase 
induced vasorelaxation in diabetic vessels (Fig. 6). 
Dose-response curves for PE and NaHS were 
shifted to the left while dose-response curves for 
SNP were shifted to the right in the db/db group 
(Fig. 7. and Fig. 8). 
  
Purpose 
We aimed to analyze the effects of SMase on 
vascular tone in diabetic conditions and to 
elucidate the signal transduction mechanisms 
involved with special emphasis on hydrogen 
sulfide. 
 
 
Materials and Methods 
Thoracic aorta segments were isolated from adult 
db/db and non-diabetic littermate male mice 
following  measurement of blood glucose levels 
and body weights. After establishing a dose-
response curve for acetyl-choline (Ach from 10-9 
to 10-5 M) the effect of 0.2 U/ml SMase was 
investigated after a precontraction with 0.1 µM 
phenylephrine under isometric conditions in 
myographs. Vascular segments were first tested 
the presence or absence of  eNOS inhibitor L-
NAME (100 µM), the selective thromboxane 
receptor (TP-R) antagonist SQ 29,548 (1 µM) or 
both. Results of these experiments are expressed 
in two ways, one showing the maximal changes in 
vascular tone in percentages and the other 
indicating  the relative level of vascular tone over 
time after the application of SMase. In the 
following experiements that were designed to 
better understand the signal transduction 
mechanisms we used sphingosine-1-phosphate 
receptor 1 inhibitor W146 (1 µM), ceramidase 
inhibitor D-erythro-MAPP (50 µM), PI3-kinase 
inhibitor Wortmannin (0.1 µM), Akt-inhibitor 
MK2206 (1 µM) and cystathionine-γ-liase (CSE) 
inhibitor propargylglycin (PAG, 10 mM). In case of 
PLC inhibitor U73122  the inactive analog U73343 
was used as a control and these drugs were given 
to the animals in perfusion. We also tested the 
dose-response relationships of phenylephrine (PE, 
10-8-10-5 M) and sodium hydrosulfide (NaHS, 10-5- 
10-3 M) and sodium nitroprusside (SNP, 10-10-10-5 
M) after precontraction induced by 1 µM 
phenylephrine. Results are expressed as 
percentage changes comparing the maximal 
contraction and maximal relaxations to the tone 
of precontraction. 
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Introduction 
Sphingolipids, derived from sphingomyelin 
metabolism, have been implicated as important 
mediators in the cardiovascular system (1-2). 
Sphingomyelinase (SMase) catalyzes the 
conversion of sphingomyelin to ceramide (3), 
which is the precursor of other sphingolipid 
mediators, e.g. shingosine-1-phosphate (S1P) (Fig. 
1). Both the endothelium and the vascular 
smooth muscle express receptors of S1P which 
mediate diverse vascular effects. On the other 
hand, sphingolipid mediators may have biological 
effects independently of the activation of S1P 
receptors. The first step of sphingolipid 
biosynthesis from sphingomyelin is catalyzed by 
sphingomyelinase (SMase) enzymes which are 
reportedly upregulated in certain cardiovascular 
and metabolic disorders such as type 2 diabetes 
mellitus (4).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
It was shown earlier by our group and others that 
sphingomyelinase (SMase) induces changes of 
vascular tone with an initial contraction and 
subsequent relaxation in aortic rings of wild type 
mice (5). However, the exact mechanisms of the 
vascular effects of sphingomyelinase on vessels 
from wild type and diabetic mice are unknown. 
Our earlier studies revealed that the effect is not 
related to S1P2 or S1P3 receptors and subsequent 
experiments indicated that the contraction is 
related to thromboxane and the relaxation is NO-
dependent. 
Recently, hydrogen sulfide (H2S) has been 
implicated as an important gasotransmitter in 
physiological and pathophysiological states (6) 
and our and others’ data indicate that it has 
profound effect on the on vascular tone (7-9). A 
possible mechanism could be its inhibitory effect 
on the phospodiesterase 5A (PDE5A) leading to 
increased levels of cGMP, thus relaxation (Fig 2.). 
Furthermore, H2S levels were shown to be altered 
in db/db mice (10) suggesting a  possible role for 
H2S in the endothelial dysfunction that is 
associated with this condition. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
Blood glucose levels and body weights of the 
investigated animals were significantly higher in 
the db/db group (Fig 3.A and B) and vessels from 
these animals developed marked endothelial 
dysfunction as  shown by the right-shift of their 
acetyl-choline dose-response curve (Fig 3.C). 
 
Fig. 3.  The investigated db/db mice developed manifest 
diabetic state as indicated by their blood glucose level (A), 
body weight (B) and endothelial dysfunction (C).(n=12-20; 
**:p<0.01; ***: p<0.001) 
SMase evoked an initial contraction (13.8±6.3 %) 
in control vessels followed by relaxation to the 
original tone, while it caused a marked relaxation 
(-21.9±7.1%) in the diabetic vessels (Fig. 4A). L-
NAME administration further increased the 
contraction (25.3±7.6 %) in the control and strong 
contraction (36.8±3.1%) occured in the diabetic 
vessels as well (Fig. 4B). TP-R inhibitor SQ 29,548 
led to relaxation in both groups, but these were 
more pronounced in the db/db group (-25.1±6.3% 
vs. -63.1±14.9%; Fig. 4C). Co-administration of the 
inhibitors resulted in no change in vascular tone 
after SMase treatment (Fig 4D). 
Fig. 1.  Pathways of sphingomyelin metabolism. 
Fig. 4.  Changes in vascular tones of thoracic aorta 
segments derived from control and db/db mice after the 
application of 0.2 U/ml SMase. Maximal relaxations or 
contractions are shown on the left and changes over time 
are presented on the right. (A) no inhibition; (B) NOS-
inhibition by L-NAME; (C) TP-R inhibition by SQ 29,548; (D) 
combined inhibition of NOS and TP-R by L-NAME and SQ 
29,548 (mean±SEM, n=7-26). 
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Fig. 5. Changes in vascular tones of thoracic aorta 
segments derived from control and db/db mice after the 
application of 0.2 U/ml SMase. Maximal relaxations are 
shown with or without the inhibition of S1P1R inhibition 
(W146, A), ceramidase blocking (D-MAPP, B), PI3K 
inhibition (wortmannin, C) and Akt inhibition (MK2206, 
D) (mean±SEM, n=2-6). 
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Fig. 6.  Relaxations in db/db derived vessels are dependent 
on PLC (A) and on CSE (B)  (mean±SEM, n=5-9). 
 
Fig. 2.  Possible involvement of H2S in 
vasorelaxation. (Modified after reference 9.) 
Fig. 8.  Dose-response curves for (A) PE; (B) SNP; (C) NaHS  
(mean±SEM, n= 5; *: p<0.05, **: p<0.01, ***: p<0.001). 
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Fig. 7.  Representative recordings of NahS and SNP dose-
repsonse experimenst from a wild type (upper, red curve) 
and a db/db mice derived vessel (lower, blue curve). 
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SMase =      Sphingomyelinase 
SM synthase =  Sphingomyelin-synthase 
CS =                     Ceramide-synthase 
C1PP =                Ceramide-1-phosphate-     
      phosphatase 
CKase =               Ceramide-kinase 
SPHK =                Sphingosine-kinase 
S1PP =                 Sphingosine-1-phosphate- 
    phosphatase 
S1P1-R =              Sphingosine-1-phosphate-1-
    receptor 
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